The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The combination of isatuximab, bortezomib, and lenalidomide with limited dexamethasone is a feasible treatment option for transplant-ineligible older patients with multiple myeloma (MM),
An interim positron emission tomography (PET) scan after four treatment cycles emerged as the strongest predictor of outcomes for primary mediastinal B-cell lymphoma
The US Food and Drug Administration (FDA) has granted clearance to the Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail, an in-situ
The Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved a phase 3 clinical trial for ICP-248
The addition of ropeginterferon alfa-2b (ropegIFNα) to phlebotomy for the treatment of polycythemia vera (PV) was “cost effective,” according to an Austrian study
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation for OPN-6602, an oral small-molecule EP300/CBP inhibitor, for patients with multiple
The US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for LTZ-301, a first-in-class bispecific myeloid engager immunotherapy,
A real-world study compared the two chimeric antigen receptor (CAR) T-cell therapies idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) for the treatment of
Measurable residual disease (MRD) negativity was associated with better response to treatment with the chimeric antigen receptor T-cell therapy obecabtagene autoleucel (obe-cel) in
The Japan Ministry of Health, Labour and Welfare has approved epcoritamab (Epkinly) as a treatment for adult patients with relapsed or refractory follicular
